Key Points Viking Therapeutics is developing a weight loss medicine in the same general class as Eli Lilly's tirzepatide. The mid-cap biotech is exploring options for a potential quadruple agonist therapy. Though Viking looks promising, there are also significant risks involved. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) produced exceptional returns over the long run and is now the largest pharmaceutical company in the world by market cap, largely thanks to its work ...